Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets |
| |
| Institution: | 1. Department of Psychiatry, Huashan Hospital, Fudan University, 200021 Shanghai, China;2. Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 200030 Shanghai, China;3. Shanghai Luwan Mental Health Center, 1162 Quxi Road, 200023 Shanghai, China;4. Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Bio-X Institutes (Ministry of Education), Shanghai Jiao Tong University, 200030 Shanghai, China);1. Department of Pharmacological and Biomolecular Sciences, University of Milan, I-20133 Milan, Italy;2. Center of Excellence on Neurodegenerative Diseases, University of Milan, I-20133 Milan, Italy;1. Department of Psychiatry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan;2. Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan;3. Department of Psychiatry, National Taiwan University Hospital Yun-Lin Branch, Yunlin County, Taiwan;4. Department of Public Health & Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan;5. Research Center for Genes, Environment and Human Health, National Taiwan University, Taipei, Taiwan;6. Department of Psychiatry, Wizcare Hospital, Taichung, Taiwan |
| |
| Abstract: | We compared the changes in weight (kg) and body mass index (BMI) (kg/m2) in 52 hospitalized adolescents between baseline and after 12 weeks of monotherapy with either (i) olanzapine (OLZ) orally disintegrating tablets (ODT) (N = 16; 16.6 mg/day ± 4.4 SD]), or (ii) OLZ standard oral tablets (SOT) (N = 10; 18.0 mg/day ± 4.2), or (iii) risperidone (N = 26; 2.8 mg/day ± 1.2). Significantly greater increases in mean weight and BMI were observed in the patients treated with OLZ SOT (8.9 ± 5.1 SD] kg; 1.9 ± 0.6 kg/m2, respectively) than in those with ODT (3.0 ± 2.1 kg; 1.1 ± 0.8 kg/m2). Similarly, OLZ ODT treatment was associated with significantly greater increases in weight and BMI than risperidone (1.0 ± 1.8 kg; 0.4 ± 0.7 kg/m2). These findings suggest that adolescents gain less weight with OLZ ODT than OLZ SOT, possibly because the former formulation shortens the time of interaction with digestive serotonin receptors mediating satiety. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
